Efficacy of Intravitreal Bevacizumab for Recurrent Central Serous Chorioretinopathy in Patients Who Had Previously Responded Well to the Same Therapy.
To investigate the efficacy of intravitreal bevacizumab therapy in the treatment of recurrent central serous chorioretinopathy (CSC) that had previously resolved after intravitreal bevacizumab administration. This retrospective, observational study included 24 eyes from 24 patients with recurrent CSC who had previously responded to intravitreal bevacizumab. Patients were classified into the responder group when resolution of serous retinal detachment was noted within 3 months after intravitreal bevacizumab (1.25 mg/0.05 mL) administration; the remaining patients were classified into the non-responder group. Patient characteristics were compared between the 2 groups. Ten eyes (42%) were included in the responder group, and 14 eyes (58%) were included in the non-responder group. Patients in the responder group were significantly older (mean age, 47.0 ± 4.5 years) than those in the non-responder group (mean age, 40.9 ± 5.5 years; P = 0.023). The visual acuity of the patients in the responder group was significantly worse than that of the patients in the non-responder group at the time of the first (mean 0.25 ± 0.15 vs. 0.13 ± 0.15) and second episodes (0.24 ± 0.14 vs. 0.14 ± 0.18; P = 0.040 and P = 0.021 for the first and second episodes, respectively). Repeated intravitreal bevacizumab can be considered a useful treatment option for relatively older patients with CSC who previously responded well to the same therapy. The results of the present study also suggest that a vascular endothelial growth factor-dependent pathologic process may be involved in CSC in older subjects.